Recognition and management of heparin-induced thrombocytopenia (HIT) and thrombosis

Seminars in Thrombosis and Hemostasis

Volumn 23, Issue 6, 1997, Pages 569-574

  Alving, Barbara M ^a   Krishnamurti, Chitra ^b  

^a WASHINGTON HOSPITAL CENTER   (United States)

^b WALTER REED ARMY INSTITUTE OF RESEARCH   (United States)

Author keywords

Antibody; Heparin; Platelet factor 4; Thrombocytopenia; Thrombosis

Indexed keywords

ARGATROBAN; DANAPAROID; DEXTRAN 40; FIBRIN GLUE; HEPARIN; HIRUDIN; IMMUNOGLOBULIN A; IMMUNOGLOBULIN G; IMMUNOGLOBULIN M; LOW MOLECULAR WEIGHT HEPARIN; THROMBOCYTE FACTOR 4; WARFARIN;

AUTOIMMUNE DISEASE; CLINICAL FEATURE; CLINICAL TRIAL; CONFERENCE PAPER; FIBRINOLYSIS; HUMAN; IMMUNOPATHOGENESIS; INTRAVENOUS DRUG ADMINISTRATION; PRIORITY JOURNAL; THROMBOCYTOPENIA; THROMBOSIS;

EID: 0031409977     PISSN: 00946176     EISSN: None     Source Type: Journal    
DOI: 10.1055/s-2007-996138     Document Type: Conference Paper

References (43)

1. Amiral J, F Bridey, M Dreyfus, AM Vissac, E Fressinaud, M Wolf, D Meyer: Platelet factor 4 complexed to heparin is the target for antibodies generated in heparin-induced thrombocytopenia (Letter). Thromb Haemostas 68:95-96, 1992.
2. Visentin GP, SE Ford, JP Scott, RH Aster: Antibodies from patients with heparin-induced thrombocytopenia/thrombosis are specific for platelet factor 4 complexes with heparin or bound to endothelial cells. J Clin Invest 93:81-88, 1994.
3. Greinacher A, B Pötzsch, J Amiral, V Dummel, A Eichner, C Mueller-Eckhardt: Heparin-associated thrombocytopenia: Isolation of the antibody and characterization of a multimolecular PF4-heparin complex as the major antigen. Thromb Haemostas 71:247-251, 1994.
4. Kelton JG, JW Smith, TE Warkentin, CPM Haywood, GA Denomme, P Horsewood: Immunoglobulin G from patients with thrombocytopenia binds to a complex of heparin and platelet factor 4. Blood 83:3232-3239, 1994.
5. Amiral J, M Wolf, A-M Fischer, C Boyer-Neumann, A-M Vissac, D Meyer: Pathogenicity of IgA and/or IgM antibodies to heparin-PF4 complexes in patients with heparin-induced thrombocytopenia. Br J Haematol 92:954-959, 1996.
6. Park KS, S Rifat, H Eck, K Adachi, S Surrey, M Poncz: Biologic and biochemical properties of recombinant platelet factor 4 demonstrate identity with native protein. Blood 75:1290-1295, 1990.
7. Greinacher A, I Michels, U Liebenhoff, P Presek, C Mueller-Eckhardt: Heparin-associated thrombocytopenia: Immune complexes are attached to the platelet membrane by the negative sulphated oligosaccharides. Br J Haematol 84:711-716, 1993.
8. Greinacher A: Antigen generation in heparin-associated thrombocytopenia: The nonimmunologic type and the immunologic type are closely linked in their pathogenesis. Thromb Haemostas 21:106-116, 1995.
9. Chong BH: Annotation. Heparin-induced thrombocytopenia. Br J Haematol 89:431-439, 1995.
10. Chong BH, RL Pilgrim, MA Cooley, CN Chesterman: Increased expression of platelet IgG Fc receptors in immune heparin-induced thrombocytopenia. Blood 81:988-993, 1993.
11. Amiral J, A Marfaing-Koka, M Wolf, MC Alessi, B Tardy, C Boyer-Neumann, AM Vissac, E Fressinaud, M Poncz, D Meyer: Presence of autoantibodies to interleukin-8 or neutrophil-activating peptide-2 in patients with heparin-associated thrombocytopenia. Blood 88:410-416, 1996.
12. Burgess JK, R Lindenman, CN Chesterman, BH Chong: Single amino acid mutation of Fcγ receptor is associated with the development of heparin-induced thrombocytopenia. Br J Haematol 91:761-766, 1995.
13. Brandt JT, CE Isenhart, JM Osborne, A Ahmed, CL Anderson: On the role of platelet Fc-gamma-RHA phenotype in heparin-induced thrombocytopenia. Thromb Haemostas 74:1564-1572, 1995.
14. 131 polymorphism, subclass-specific IgG antiheparin/plalelet factor 4 antibodies and clinical course in patients with heparin-induced thrombocytopenia and thrombosis. Blood 89:370-375, 1997.
15. Suh J-S, MI Malik, RH Aster, GP Visentin: Characterization of the humoral immune response in heparin-induced thrombocytopenia. Am J Hematol 54:196-201, 1997.
16. Warkentin TE, CPM Hayward, LK Boshkov, AV Santos, JAI Sheppard, AR Bode, JG Kelton: Sera from patients with heparin-induced thrombocytopenia generate platelet-derived microparticles with procoagulant activity: An explanation for the thrombotic complications of heparin-induced thrombocytopenia. Blood 84:3691-3699, 1994.
17. Shibata S, PC Harpel, A Gharavi, J Rand, H Fillit: Autoantibodies to heparin from patients with antiphospholipid antibody syndrome inhibit formation of antithrombin III-thrombin complexes. Blood 83:2532-2540, 1994.
18. Cummins D, O Halil, S Amin: Which patients undergoing cardiopulmonary bypass should be assessed for development of heparin-induced thrombocytopenia? Thromb Haemostas 73: 890-891, 1995.
19. Hach-Wunderle V, K Kainer, B Krug, G Müller-Berghaus, B Pötzsch: Heparin-associated thrombosis despite normal platelet counts (Letter). Lancet 344:469-470, 1994.
20. Warkentin TE: Heparin-induced skin lesions. Br J Haematol 92:494-497, 1996.
21. Boshkov LK, TE Warkentin, CPM Hayward, M Andrew, JG Kelton: Heparin-induced thrombocytopenia and thrombosis: Clinical and laboratory studies. Br J Haematol 84:322-328, 1993.
22. Jackson MR, C Krishnamurti, CA Aylesworth, BM Alving: Diagnosis of heparin-induced thrombocytopenia in the vascular surgery patient. Surgery 121:419-424, 1997.
23. Warkentin TE, JG Kelton: A 14-year study of heparin-induced thrombocytopenia. Am J Med 101:502-507, 1996.
24. 14C-serotonin release assay in the diagnosis of heparin-induced thrombocytopenia. Am J Clin Pathol 104:648-654, 1995.
25. Warkentin TE, MN Levine, J Hirsh, P Horsewood, RS Roberts, M Gent, JG Kelton: Heparin-induced thrombocytopenia in patients treated with low-molecular-weight heparin or unfractionated heparin. N Engl J Med 332:1330-1335, 1995.
26. Warkentin TE, CPM Hayward, CA Smith, PM Kelly, JG Kelton: Determinants of donor platelet variability when testing for heparin-induced thrombocytopenia. J Lab Clin Med 120:371-379, 1992.
27. Amiral J, JA Bridey, M Wolf, B Boyer-Neumann, E Fressinaud, AM Vissac, E Peynaud-Debayle, M Dreyfus, D Meyer: Antibodies to macromolecular platelet factor 4-heparin complexes in heparin-induced thrombocytopenia: A study of 44 cases. Thromb Haemostas 73:21-28, 1995.
28. Ortel TL, JP Gockerman, RM Califf, RL McCann, CM O'Connor, DM Metzler, CS Greenberg: Parenteral anticoagulation with the heparinoid Lomoparan (Org 10172) in patients with heparin-induced thrombocytopenia and thrombosis. Thromb Haemostas 67:292-296, 1992.
29. Magnani HN: Heparin-induced thrombocytopenia (HIT): An overview of 230 patients treated with Orgaran (Org 10172). Thromb Haemostas 70:554-561, 1993.
30. Matsuo T, K Kario, Y Chikahira, K Nakao, T Tamada: Treatment of heparin-induced thrombocytopenia by use of argatroban, a synthetic thrombin inhibitor. Br J Haematol 82:627-629, 1992.
31. Parent F, F Bridey, M Dreyfus, D Musset, G Girmon, P Duroux, D Meyer, G Simonneau: Treatment of severe venous thromboembolism with intravenous hirudin (HBW 023): An open pilot study. Thromb Haemostas 70:386-388, 1993.
32. Schiele F, A Vuillemenot, P Kramarz, Y Kieffer, T Anguenot, Y Bernard, JP Bassand: Use of recombinant hirudin as antithrombotic treatment in patients with heparin-induced thrombocytopenia. Am J Hematol 50:20-25, 1995.
33. Nand S: Hirudin therapy for heparin-associated thrombocytopenia and deep vein thrombosis. Am J Hematol 43:310-311, 1993.
34. Hijikata-Okunomiya A, S Okamoto: A strategy for a rational approach to designing synthetic selective inhibitors. Semin Thromb Hemostas 18:135-149, 1992.
35. Berry CN, C Girardot, C Lecoffre, C Lunven: Effects of the synthetic thrombin inhibitor argatroban on fibrin-or clot-incorporated thrombin: Comparison with heparin and recombinant hirudin. Thromb Haemostas 72:381-386, 1994.
36. Schwarz, RP Jr, J-C Becker, RL Brooks, MC Hursting, JL Joffrion, GD Knappenberger, TP Kogan, PW Kogan, AA McKinney: The preclinical and clinical pharmacology of Novastan (argatroban): A small-molecule, direct thrombin inhibitor. J Clin Appl Thromb Hemost 3:1-15, 1997.
37. Lewis BE, R Iaffaldano, TH McKiernan, L Rao, J Donkin, JM Wallenga: Report of successful use of argatroban as an alternative anticoagulant during coronary stent implantation in a patient with heparin-induced thrombocytopenia and thrombosis syndrome. Cathet Cardiovasc Diagn 38:206-209, 1996.
38. Bauer TL, G Arepally, BA Konkle, B Mestichelli, SS Shapiro, OB Cines, M Poncz, S McNulty, J Amiral, WW Hauck, RN Edie, JD Mannion: Prevalence of heparin-associated antibodies without thrombosis in patients undergoing cardiopulmonary bypass surgery. Circulation 95:1242-1246, 1997.
39. Visentin GP, M Malik, KA Cyganiak, RH Aster: Patients treated with unfractionated heparin during open heart surgery are at high risk to form antibodies reactive with heparin: Platelet factor 4 complexes. J Lab Clin Med 128:376-383, 1996.
40. Jackson MR, CA Danby, BM Alving: Heparinoid anticoagulation with topical human fibrin sealant during cardiac surgery in a patient with heparin-induced thrombocytopenia. Ann Thorac Surg 1997 (in press).
41. Magnani HN, RJR Beijering, JW Ten Cate, BH Chong: Orgaran anticoagulation for cardiopulmonary bypass in patients with heparin-induced thrombocytopenia. In: Pifarre R (ed): New Anticoagulants for the Cardiovascular Patient. Hanley and Belfus, Philadelphia, 1997, pp 487-500.
42. Marshall LR, PK Cannell, RP Herrmann: Successful use of the aPTT in monitoring the heparinoid Organon 10172 in a case of HITS requiring open heart surgery (Letter). Thromb Haemostas 67:587, 1992.
43. Warkentin TE: Heparin-induced thrombocytopenia: IgG-mediated platelet activation, platelet microparticle generation, and altered procoagulant/anticoagulant balance in the pathogenesis of thrombosis and venous limb gangrene complicating heparin-induced thrombocytopenia. Trans Med Rev 10:249-258, 1996.